Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Deferred Taxes (2017 - 2025)

Corcept Therapeutics' Deferred Taxes history spans 9 years, with the latest figure at -$15.2 million for Q4 2025.

  • For Q4 2025, Deferred Taxes fell 293.52% year-over-year to -$15.2 million; the TTM value through Dec 2025 reached -$37.5 million, up 6.6%, while the annual FY2025 figure was -$37.5 million, 6.6% up from the prior year.
  • Deferred Taxes for Q4 2025 was -$15.2 million at Corcept Therapeutics, down from $9.1 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $9.1 million in Q3 2025 and bottomed at -$17.8 million in Q2 2025.
  • The 5-year median for Deferred Taxes is -$8.0 million (2023), against an average of -$6.8 million.
  • The largest annual shift saw Deferred Taxes crashed 678.8% in 2022 before it surged 159.93% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at $2.3 million in 2021, then crashed by 294.3% to -$4.5 million in 2022, then grew by 17.8% to -$3.7 million in 2023, then decreased by 5.07% to -$3.9 million in 2024, then crashed by 293.52% to -$15.2 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Deferred Taxes are -$15.2 million (Q4 2025), $9.1 million (Q3 2025), and -$17.8 million (Q2 2025).